Search Results

You are looking at 131 - 140 of 1,575 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, and Ines Vaz-Luis

−. Patients with >1 disease site were assigned to the category of the first site listed, according to a prespecified ranking system defined by importance. Table 1. Patient Demographics and Clinicopathologic Characteristics (n=302) Central

Full access

Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis

Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group

was captured via the home care database. Covariates are detailed in supplemental eTable 3 . Statistical Analysis Descriptive statistics evaluated characteristics of the overall cohort and stratified by frailty status. Continuous variables were

Full access

Metastatic Versus Osteoporotic Vertebral Fractures on MRI: A Blinded, Multicenter, and Multispecialty Observer Agreement Evaluation

Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Fatima Nagib, Sandra Pérez-Aguilera, María Dejoz, Alberto Cabrera-Zubizarreta, Yolanda García-Hidalgo, Ana Estremera, and for the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis

years. Table 1 also shows the characteristics of the 203 patients whose clinical histories and images were selected for the study and of the 25 readers who interpreted their data. Table 1. Sample Characteristics As Table 2 shows, interobserver

Full access

Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care

Briony Shaw, Catriona Parker, Stephen Opat, Jake Shortt, and Peter Poon

these were enrolled in a clinical study at the time of death, with many being early-phase drug trials for relapsed or refractory disease. Figure 1. CONSORT diagram. Table 1. Patient Characteristics Place of Death Of all patients

Full access

Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group*

summarize sample characteristics, analyze feasibility/acceptability, and summarize secondary outcomes. We compared self-efficacy scores preintervention and postintervention using multilevel models (MIXED function). Results Of 36 eligible and contactable

Full access

Understanding Comorbidity Profiles and Their Effect on Treatment and Survival in Patients With Colorectal Cancer

Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry, and Ernest Shen

adjusted for multiple pairwise comparisons between comorbidity classes by using the Bonferroni correction. Table 1. Patient Characteristics, Cancer Treatment, and Comorbidities Results We identified 7,803 patients with CRC ( Table 1

Full access

Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery

Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen, and Li Zhu

than stage IV, unknown demographic characteristics and follow-up, or unknown involvement of bone, brain, liver, or lung, and those diagnosed at autopsy or via death certificate were excluded. Eligible patients were divided randomly into the training or

Full access

Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series

Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao

of expression. After 3 cycles of pembrolizumab, restaging PET/CT demonstrated greater diminishment of the antral tumor and stable intrathoracic nodes. Table 1. Summary of Patient Characteristics, Treatments, and Responses Figure 1

Full access

Regional Variations in Clinical Trial Outcomes in Oncology

Brooke E. Wilson, Sallie-Anne Pearson, Michael B. Barton, and Eitan Amir

breast (n=23; 16%). The mean number of participating patients, sites, and countries were similar between studies that presented regional analyses and those that did not ( Table 1 ). Table 1. Baseline Trial Characteristics (N=147) Among all 147

Full access

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad

not available for analysis. Univariate analysis was applied to compare characteristics of participants who did and did not undergo surgical resection using Student t tests for continuous variables and Fisher exact for categorical variables